A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00354445

Enrollment

1000

Registered

2006-07-20

Start date

2006-06-30

Completion date

Unknown

Last updated

2007-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration (AMD)

Keywords

Age-Related Macular Degeneration (AMD), pegaptanib sodium, subfoveal CNV, macugen

Brief summary

The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.

Interventions

DRUGpegaptanib sodium (Macugen)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subfoveal CNV secondary to AMD * At least 1 but not more than 3 prior treatments for AMD

Exclusion criteria

* Subfoveal scar or subfoveal atrophy * Significant media opacities, including cataract, which might interfere with visual acuity

Countries

United States

Contacts

Primary ContactMacugen Information

1-866-622-8436

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026